Critically ill COVID | 合法醫療器材資訊網

由SDeRosa著作—PolymyxinBhemoperfusionhasobtainedIDEauthorizationfromFDAforthetreatmentofCOVID-19patientswithsepticshockandHealthCanadahasauthorized ...

Over the last year, various works in literature have revealed the potential role of Polymyxin B Hemoperfusion in the management of non-responsive COVID-19 patients admitted to intensive care.

Patients who are undergoing long periods of hospitalization are more prone to superinfections. In addition, enteric symptoms, as well as the increasingly described ‘gut-lung’ interactions due to bacterial transmigration and/or their components caused by changes in the intestinal membrane (microbiotic dysbiosis), lead to the systemic circulation of endotoxin[1].

Considering Polymyxin B Hemoperfusion in the context of COVID-19 and a concomitant state of superinfection and/or endotoxemia leading to a severe a clinical picture (septic shock) not responsive to standard therapy is therefore rational and pragmatic, as described in various publications [2-4].

Polymyxin B hemoperfusion has obtained...